Advertisement

China coronavirus vaccine candidate appears safe for older people: preliminary results

Click to play video: 'Coronavirus: WHO says widespread COVID-19 vaccinations not expected until mid-2021'
Coronavirus: WHO says widespread COVID-19 vaccinations not expected until mid-2021
WATCH: Coronavirus: WHO says widespread COVID-19 vaccinations not expected until mid-2021 – Sep 4, 2020

Chinese firm Sinovac Biotech Ltd said on Monday its coronavirus vaccine candidate appeared to be safe for older people, according to preliminary results from an early to mid-stage trial, while the immune responses triggered by the vaccine were slightly weaker than younger adults.

Health officials have been concerned about whether experimental vaccines could safely protect the elderly, whose immune systems usually react less robustly to vaccines, against the virus that has led to nearly 890,000 deaths worldwide.

Sinovac’s candidate CoronaVac did not cause severe side effects in a combined Phase 1 and Phase 2 trials launched in May involving 421 participants aged at least 60, Liu Peicheng, Sinovac’s media representative, told Reuters.

The complete results have not been published and were not made available to Reuters.

Story continues below advertisement

Four of the world’s eight vaccines that are in the third phase of trials are from China.

Receive the latest medical news and health information delivered to you every Sunday.

Get weekly health news

Receive the latest medical news and health information delivered to you every Sunday.
By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy.

For three groups of participants who respectively took two shots of low, medium and high-dose CoronaVac, over 90 per cent of them experienced significant increase in antibody levels, while the levels were slightly lower than those seen in younger subjects but in line with expectation, Liu said in a statement.

Click to play video: 'Fauci on his fears, a COVID-19 vaccine, Canada-U.S. border restrictions'
Fauci on his fears, a COVID-19 vaccine, Canada-U.S. border restrictions

CoronaVac, being tested in Brazil and Indonesia in the final-stage human trials to evaluate whether it is effective and safe enough to obtain regulatory approvals for mass use, has already been given to tens of thousands of people, including about 90 per cent of Sinovac employees and their families, as part of China’s emergency inoculation scheme to protect people facing high infection risk.

The potential vaccine could remain stable for up to three years in storage, Liu said, which might offer Sinovac some advantage in vaccine distribution to regions where cold-chain storage is not an option.

Story continues below advertisement

Such estimation is extrapolated from the fact that vaccines readings stayed within acceptable ranges for 42 days at 25 C, 28 days at 37 C , and five months for 2-8 C, Liu said, without disclosing complete data.

Sponsored content

AdChoices